Meet Dr. Steve Slilaty
Professor, Doctor, CEO, Visionary
Dr. Slilaty is an accomplished scientist and a highly skilled business executive.
He received his Bachelor of Science degree in Genetics and Biochemistry from Cornell University and his Ph.D. in Molecular Biology & Biochemistry from the University of Arizona.
Dr. Slilaty is a leader in the bioscience industry and is referenced in editorials, reviews and textbooks.
His extensive contributions to science included the discovery of a new class of enzymes (IUBMB Enzyme: EC 18.104.22.168) and the development of key technology for the Human Genome Project (TrueBlue Cloning System).
With a passion for medicine, he founded three biotech companies and took one public. The company he took public, Genomics One Corporation reached $1 billion market cap.
At Sunshine Biopharma Dr. Slilaty is working with the same determination as he pioneers a path towards the discovery of ground breaking drugs for the treatment of aggressive forms of cancer.
What is Adva-27a?
Our Flagship AntiCancer Drug
Our flagship anticancer compound is Adva-27a, a GEM-difluorinated C-glycoside derivative of Podophyllotoxin, targeted for various forms of cancer (See 3D Molecular Model below).
Adva-27a is expected to enter Phase I clinical trials for pancreatic cancer and multidrug resistant breast following completion of the GMP manufacturing and formulation of a 2-kilograms quantity for injection.
The mechanism by which Adva-27a is able to destroy cancer cells is through the inhibition of a key cell-cycle enzyme called Topoisomerase II. Unlike other antitumor drugs currently in use, Adva-27a is able to destroy multidrug resistant cancer cells.
US Patent Number 8,236,935 covering Adva-27a was issued on August 7, 2012.
Sunshine Biopharma is direct owner of this as well as all right, title and interest in and to all worldwide patents covering Adva-27a, including all issued and pending patents under PCT/FR2007/000697 and PCT/CA2014/000029.
Sunshine Biopharma has not granted any licenses or rights to any entity under these patents.
In Short, This is the Real Deal
Adva-27a is effective at killing different types of multidrug resistant cancer cells, including:
Breast Cancer Cells (MCF-7/MDR)
Small Cell Lung Cancer Cells (H69AR)
Uterine Cancer (MES-SA/Dx5)
Pancreatic Cancer (Panc-1)
Adva-27a is unaffected by P-Glycoprotein, the enzyme responsible for making cancer cells resistant to anti-tumor drugs.
Adva-27a has excellent clearance time (half-life = 54 minutes) as indicated by human microsomes stability studies and pharmacokinetics data in rats.
And much, much more. Read more by clicking the button.
We're Also Working On
Generic Drugs - Coming Soon
SBI-Anastrozole for treatment of Breast Cancer
SBI-Letrozole for treatment of Breast Cancer
SBI-Bicalutamide treatment of Prostate Cancer
SBI-Finasteride for treatment of BPH (Benign Prostatic Hyperplasia)
By prescription only.
Not available in the United States.